Everolimus, a mTOR inhibitors, has been approved by FDA for the treatment of hormone receptors positive and HER2 negative advanced postmenopausal breast cancer patients, hoping to overcome or slowdown the development of endocrine resistance. This evidence concerns the gene ERBB2 and breast cancer.